Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Johnson & Johnson, a leading name in the medical and precision instruments industry, is headquartered in the United States. Founded in 1886, the company has established itself as a pioneer in healthcare, focusing on medical devices, pharmaceuticals, and consumer health products. With a strong presence in North America, Europe, and Asia, Johnson & Johnson operates across various sectors, including surgical instruments and orthopaedic devices.
Renowned for its innovative approach, Johnson & Johnson offers a diverse range of core products, including advanced surgical tools and cutting-edge diagnostic equipment. The company’s commitment to quality and safety has positioned it as a trusted leader in the industry. Notable achievements include significant advancements in minimally invasive surgery and a robust portfolio of patented technologies, solidifying its market position as a frontrunner in healthcare solutions.
-6 vs industry average
Johnson & Johnson’s score of 26 is lower than 44% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medical Device Manufacturing has below-average carbon intensity
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Scope 3 accounts for ••• of total emissions.
Johnson & Johnson, a US-based company in the Medical, precision and optical instruments, watches and clocks industry, reported combined Scope 1 and 2 emissions of approximately 430,926,000 kg CO2e in 2024. This marks a reduction from their 2023 combined Scope 1 and 2 emissions of approximately 456,871,000 kg CO2e and their 2022 emissions of approximately 514,693,000 kg CO2e.
The company has achieved a 26% reduction in its absolute Scope 1 and 2 greenhouse gas emissions since 2021. Johnson & Johnson is committed to further climate action, aiming to be a net-zero carbon emissions (Scope 1 and 2) business by 2045. Additionally, the company has set a near-term target to reduce its Scope 1 and 2 emissions by 29% by 2030, using 2023 as a baseline.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Johnson & Johnson yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more